|
|
|
|
A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study
Oncology (Karger), 02/03/10 Relevance Score: 80% International Journal of Cancer, 01/21/10 Relevance Score: 67% Journal of Pediatric Surgery, 01/12/10 Relevance A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus ...
|
|
|
TopoTarget signs co-development and commercialization agreement with Spectrum Pharmaceuticals
Spectrum Pharmaceuticals, Inc., a US-based biotechnology company, has entered into a co-development and commercialization agreement with TopoTarget A/S, a Denmark-based biotechnology company, for Belinostat, a novel histone deacetylase (HDAC) inhibitor.Under...
|
|
|
TopoTarget Partner, Spectrum Pharmaceuticals, to host Conference Call Thursday 4 February 2010 at 19:00 CET (1
- TopoTarget A/S (NASDAQ-OMX: TOPO.CO) and Spectrum Pharmaceuticals Inc.(NASDAQ: SPPI) announced on 2 February 2010 (Announcement No 02-10) an agreement to co-develop and commercialize belinostat, TopoTarget's lead anticancer drug for cancer in North America...
|
|
|
TopoTarget Partner, Spectrum Pharmaceuticals, to host Conference Call Thursday 4 February 2010 at 19:00 CET (1
TopoTarget A/S Symbion Fruebjergvej 3 DK 2100 Copenhagen Denmark Tel: +45 39 17 83 92 Fax: +45 39 17 94 92 CVR-nr: 25695771 www.topotarget.com Copenhagen, Denmark - 4 February, 2010 - TopoTarget A/S (NASDAQ-OMX: TOPO.CO) and Spectrum Pharmaceuticals Inc....
|
|
|
Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or refractory brain or spinal cord tumors
Morgan RJ et al.The recommended phase II doses are: tamoxifen 100 mg po bid, topotecan 0. Plasma and cerebrospinal fluid pharmacokinetics of topotecan in a phase I trial of topotecan, tamoxifen, and carboplatin, in the treatment of recurrent or...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, A Novel Anticancer Drug In A Pivotal Registrational Trial
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, A Novel Anticancer Drug In A Pivotal Registrational Trial
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone...
|
|
|
Spectrum Pharma licenses lymphoma drug belinostat from TopoTarget for up to $350 million
Keywords: Spectrum Pharma, TopoTarget, Belinostat, Lymphoma, PTCL Related Articles 8 January 2010 24 December 2009 18 December 2009 14 December 2009 Recent Articles 3 February 2010 3 February 2010 3 February 2010 Related Discussion There are no related...
|
|
|
Spectrum buys cancer pipeline for $350 mn
Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone deacetylase (HDAC) inhibitor.Belinostat...
|
|
|
Chemotherapy Resistance as a Predictor of Progression-Free Survival in Ovarian Cancer Patients Treated with Neoadjuvant Chemotherapy and Surgical Cytoreduction Followed by Intraperitoneal Chemotherapy: A Southwest Oncology Group Study
Clinical Trial Note Amy D.Tierstena, James Moonb, Harriet O. Smithc, Sharon P. Wilczynskid, William R. Robinson, 3rde, Maurie Markmanf, David S. Albertsg aNew York University Cancer Center, New York, N.Y.,bSouthwest Oncology Group Statistical Center,...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
Belinostat, a HDAC Inhibitor, is Currently in a Multicenter, Registrational Trial Under a Special Protocol Assessment for Peripheral T-Cell Lymphoma (PTCL) NDA Filing Expected Next Year (in 2011) Granted Fast Track and Orphan Drug Designation by FDA Multiple...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
Belinostat, a HDAC Inhibitor, is Currently in a Multicenter, Registrational Trial Under a Special Protocol Assessment for Peripheral T-Cell Lymphoma (PTCL) NDA Filing Expected Next Year (in 2011) Granted Fast Track and Orphan Drug Designation by FDA Multiple...
|
|
|
Spectrum Pharmaceuticals, Inc. (SPPI) Licenses Belinostat from TopoTarget A/S for $
* Belinostat, a HDAC Inhibitor, is Currently in a Multicenter, Registrational Trial Under a Special Protocol Assessment for Peripheral T-Cell Lymphoma (PTCL) - NDA Filing Expected Next Year (in 2011) - Granted Fast Track and Orphan Drug Designation by FDA *...
|
|
|
Spectrum and Topotarget
Spectrum buying into cancer drug which is potential blockbuster.Not cheap, but probably worth it... Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial Belinostat, a HDAC Inhibitor, is Currently in a...
|
|
|
Spectrum Pharmaceuticals, Inc. (SPPI) Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational
IRVINE, Calif--(BUSINESS WIRE)--Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a...
|
|
|
Spectrum Pharmaceuticals, Inc. (SPPI) Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational
IRVINE, Calif--(BUSINESS WIRE)--Spectrum Pharmaceuticals, a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
(BUSINESS WIRE) ------Granted Fast Track and Orphan Drug Designation by FDA --Multiple Phase 2 Trials Are Being Pursued In Various Oncology Indications Including Carcinoma Of Unknown Primary (CUP) For Which No Drug Has Yet Been Approved --National Cancer...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
(BUSINESS WIRE) ------Granted Fast Track and Orphan Drug Designation by FDA --Multiple Phase 2 Trials Are Being Pursued In Various Oncology Indications Including Carcinoma Of Unknown Primary (CUP) For Which No Drug Has Yet Been Approved --National Cancer...
|
|
|
Spectrum Pharma Enters Into Co-development And Commercialization Agreement With TopoTarget For Belinostat
(RTTNews) - Spectrum Pharmaceuticals Inc.(SPPI: News ) announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a histone deacetylase inhibitor. Belinostat is currently in a registrational...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone...
|
|
|
Spectrum Pharmaceuticals signs co-development and commercialization agreement with TopoTarget A/S
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal
BusinessWire - --Granted Fast Track and Orphan Drug Designation by FDA --Multiple Phase 2 Trials Are Being Pursued In Various Oncology Indications Including Carcinoma Of Unknown Primary (CUP) For Which No Drug Has Yet Been Approved --National Cancer Institute ...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
IRVINE, Calif--(BUSINESS WIRE)--Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
IRVINE, Calif--(BUSINESS WIRE)-- Spectrum Pharmaceuticals (NasdaqGM: SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S...
|
|
|
Spectrum Pharmaceuticals Licenses Belinostat, a Novel Anticancer Drug in a Pivotal Registrational Trial
Spectrum Pharmaceuticals (NasdaqGM:SPPI), a commercial-stage biotechnology company with a primary focus in oncology, today announced that it has entered into a co-development and commercialization agreement with TopoTarget A/S for Belinostat, a novel histone...
|
